194 related articles for article (PubMed ID: 23530969)
1. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
[TBL] [Abstract][Full Text] [Related]
2. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Ataga K; Reid M; Vichinsky EP; Neumayr L; Blair-Britt L; Labotka R; Glass J; Keefer JR; Wargin WA; Berenson R; Perrine SP
Am J Hematol; 2012 Nov; 87(11):1017-21. PubMed ID: 22887019
[TBL] [Abstract][Full Text] [Related]
3. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.
Inati A; Kahale M; Perrine SP; Chui DH; Taher AT; Koussa S; Abi Nasr T; Abbas HA; Ghalie RG
Br J Haematol; 2014 Feb; 164(3):456-8. PubMed ID: 24224649
[No Abstract] [Full Text] [Related]
5. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
Patthamalai P; Fuchareon S; Chaneiam N; Ghalie RG; Chui DH; Boosalis MS; Perrine SP
Blood; 2014 Mar; 123(12):1956-7. PubMed ID: 24652964
[No Abstract] [Full Text] [Related]
7. Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
Perrine SP; Castaneda SA; Boosalis MS; White GL; Jones BM; Bohacek R
Ann N Y Acad Sci; 2005; 1054():257-65. PubMed ID: 16339673
[TBL] [Abstract][Full Text] [Related]
8. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Yasara N; Wickramarathne N; Mettananda C; Silva I; Hameed N; Attanayaka K; Rodrigo R; Wickramasinghe N; Perera L; Manamperi A; Premawardhena A; Mettananda S
Sci Rep; 2022 Feb; 12(1):2752. PubMed ID: 35177777
[TBL] [Abstract][Full Text] [Related]
9. α-Haemoglobin stabilising protein expression is influenced by mean cell haemoglobin and HbF levels in HbE/β-thalassaemia individuals.
Lim WF; Muniandi L; George E; Sathar J; Teh LK; Gan GG; Lai MI
Blood Cells Mol Dis; 2012 Jan; 48(1):17-21. PubMed ID: 22079025
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
11. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
12. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.
Fathallah H; Taher A; Bazarbachi A; Atweh GF
Blood Cells Mol Dis; 2009; 43(1):58-62. PubMed ID: 19346141
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
[TBL] [Abstract][Full Text] [Related]
14. The role of heterocellular hereditary persistence of fetal haemoglobin in beta(0)-thalassaemia intermedia.
Chang YP; Littera R; Garau R; Smith KD; Dover GJ; Iannelli S; Cacace E; Contu L
Br J Haematol; 2001 Sep; 114(4):899-906. PubMed ID: 11564083
[TBL] [Abstract][Full Text] [Related]
15. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients.
Fibach E; Bianchi N; Borgatti M; Zuccato C; Finotti A; Lampronti I; Prus E; Mischiati C; Gambari R
Eur J Haematol; 2006 Nov; 77(5):437-41. PubMed ID: 16939628
[TBL] [Abstract][Full Text] [Related]
16. Fetal globin gene inducers: novel agents and new potential.
Perrine SP; Castaneda SA; Chui DH; Faller DV; Berenson RJ; Siritanaratku N; Fucharoen S
Ann N Y Acad Sci; 2010 Aug; 1202():158-64. PubMed ID: 20712788
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.
Zeng YT; Huang SZ; Ren ZR; Lu ZH; Zeng FY; Schechter AN; Rodgers GP
Br J Haematol; 1995 Jul; 90(3):557-63. PubMed ID: 7646994
[TBL] [Abstract][Full Text] [Related]
18. Clinical and haematological evaluation of beta thalassaemia intermedia characterised by unusually low Hb F and increased Hb A2: beta thalassaemia intermedia II.
Gurgey A; Kayin S; Kansu E; Altay C
J Med Genet; 1985 Jun; 22(3):213-21. PubMed ID: 2409284
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
20. HbF in HbE/β-thalassemia: A clinical and laboratory correlation.
Lim WF; Muniandi L; George E; Sathar J; Teh LK; Lai MI
Hematology; 2015 Jul; 20(6):349-53. PubMed ID: 25243862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
